Across TCGA pan-cancer cohorts, RN7SL470P RNA differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of RN7SL470P’s most consistent transcriptional readouts.
The strongest signal is observed in bladder urothelial carcinoma (BLCA), where RN7SL470P RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RN7SL470P is over-expressed in tumor.
BLCA and STAD are the cancer types where RN7SL470P tumor–normal differential expression is most reproducible.